Member Info for A1M4

How many people are potentially exposed?

There were 147 people – 88 passengers and 59 crew members – aboard the MV Hondius, according to the World Health Organization.

Those on board represent 23 nationalities, including 17 Americans.

Authorities are completing additional contact tracing of 82 passengers and six crew members from an April 25 Airlink flight to Johannesburg from Saint Helena that a Dutch woman who had been on the ship took before she died.

KLM said authorities in the Netherlands have also reached out to an undisclosed number of passengers on a second flight that the Dutch woman briefly boarded in Johannesburg. She left the 11:15 p.m. flight, KL592, before it took off because she was too sick to fly.

Swiss authorities are carrying out additional contact tracing for people who came into contact with a passenger who left the MV Hondius in late April and is being treated at a Swiss hospital, according to Switzerland’s health ministry. The patient’s wife, who was also on the trip, has not reported symptoms and is isolating as a precaution, the Swiss health ministry said.

In the US, the Department of State is in direct contact with passengers, and state departments of health are also involved. The Georgia Department of Public Health says it is monitoring two Georgia residents who returned home from the ship but have shown no signs of infection. An Arizona resident who was a passenger on the ship has not had symptoms and is being monitored by public health workers, according to the Arizona Department of Health. California, Texas, and Virginia are also monitoring passengers. None is exhibiting signs of the illness.

Governments are also tracking at least 30 passengers who disembarked at the remote South Atlantic island of Saint Helena in late April, and others who went through other ports, leaving for a variety of countries, all before the outbreak was fully understood.

Novacyt’s investment in Southern Cross Diagnostics is a well‑timed, strategic step that strengthens its position in a market where it’s already seeing strong momentum. The deal adds immediate commercial benefits while creating room for meaningful long‑term growth across Australia and the wider Asia‑Pacific region.

- Direct access to a rapidly expanding Australian diagnostics market with strong momentum.

- A fast‑growing, profitable distributor joining the group at exactly the right time.

- Immediate improvement to Novacyt’s earnings and overall margin profile.

- A stronger platform to grow high‑value CF and DPYD tests with positive reimbursement support.

- Closer relationships with major pathology networks and key decision‑makers.

- Founder‑CEO Nick Thliveris staying on to drive growth and maintain trusted customer ties.

- A clear vote of confidence as the founder commits up to AUD 0.8m of his own capital.

- A performance‑based earnout of up to AUD 16.5m, directly tied to ambitious EBITDA growth.

- A solid foundation for broader Asia‑Pacific expansion and new distribution opportunities.

Hospitals in Melbourne actively testing suspected cases of infectious Nipah virus

https://www.abc.net.au/listen/programs/melbourne-drive/drive-exclusive-nipah-virus-testing-in-melbourne/106343058

One of the two nurses infected with the Nipah virus in West Bengal has died following prolonged treatment at a private hospital.

https://www.newindianexpress.com/nation/2026/Feb/12/west-bengal-records-first-nipah-death-as-one-of-two-infected-nurses-dies

Three specific buy orders landed between 15:42 and 15:47, all clustered within a five‑minute window.

10-Feb-26 15:47:28 34.9022 5,730 Buy* 34.70 35.00 2,000 O

10-Feb-26 15:42:48 34.9253 11,453 Buy* 34.70 35.00 4,000 O

10-Feb-26 15:42:10 34.9256 11,452 Buy* 34.70 35.00 4,000 O

The World Health Organization said on Friday that a woman had died in northern Bangladesh in January after contracting the deadly Nipah virus infection.

https://www.theguardian.com/world/2026/feb/07/one-person-dead-from-nipah-virus-in-bangladesh-who-says

https://www.who.int/emergencies/disease-outbreak-news/item/2026-DON594

Thailand – Suvarnabhumi, Don Mueang; temperature checks and screening for India arrivals.

Nepal – Tribhuvan Int’l; screening for India arrivals and land‑border checks.

Taiwan – Major airports; extra surveillance for travellers from India.

Singapore – Changi; temperature checks and monitoring of high‑risk arrivals.

Hong Kong – HKIA; temperature checks and monitoring of India travellers.

Malaysia – KLIA and others; temperature checks and screening from outbreak areas.

Pakistan – All international airports; mandatory screening, thermal scans, travel‑history checks.

China – Major ports of entry; heightened vigilance and monitoring of travellers from affected regions.

Macao – Macao International Airport; early‑detection protocols and standby quarantine facilities.

Bangladesh – Dhaka Hazrat Shahjalal Int’l; temperature checks and monitoring of travellers from India.

Sri Lanka – Bandaranaike Int’l; health surveillance and monitoring of arrivals from affected regions.

UAE – Dubai, Abu Dhabi, Sharjah; health advisories and targeted monitoring of passengers from South Asia.

The UK Government and the UK Health Security Agency updated their Nipah virus guidance today, underscoring that they are treating the situation with full seriousness. UKHSA is actively monitoring international developments and maintaining close surveillance. Today’s update demonstrates that the authorities are staying vigilant and prepared as the situation evolves.

Primerdesign already has a validated Nipah virus PCR test in its portfolio, and the company should be promoting this capability consistently. In periods of heightened global attention and increased public‑health monitoring, having a ready‑to‑deploy diagnostic assay is a strategic advantage, and Primerdesign is well positioned to support any future testing requirements should the situation develop further.

https://ukhsa.blog.gov.uk/2026/01/27/nipah-virus-what-is-it-where-is-it-found-and-how-does-it-spread/

SP Angel has now issued two Healthcare Conditions reports since the NIPT tender award, and both show an increase in Novacyt’s market capitalisation and reported share price. In the first note, the company was valued at £28.1m with a share price of 33.79p. In the latest report, those figures have risen to £30.5m and approximately 44p. Although the live market price is currently lower, the progression across SP Angel’s own reports reflects an upward adjustment in their stated valuation metrics following the tender award.

While the large-scale national tender for the new "Single NHS GMS" model is still being finalised, Novacyt is currently in a strong position because it already provides specialised diagnostic tests to Cambridge University Hospitals. This current contract is specifically timed to end on April 30, 2026, which perfectly aligns with the launch of the new national model scheduled to begin on April 1, 2026. Because Cambridge University Hospitals has been selected as one of only seven lead trusts responsible for managing the entire £5.175 billion service through 2034, Novacyt's existing role makes it a natural partner for the transition. Since their technology is already verified and in use by a lead provider at the exact moment the new framework takes shape, there is a clear path for this supply relationship to continue under the new long-term structure.

"Agilus Diagnostics has successfully enhanced its NIPT workflow by adopting the Yourgene MagBench Automated cfDNA Extraction System, supported through seamless coordination with Yourgene Health, UK and Decipher Genomics & Research."

https://www.linkedin.com/posts/decipher-genomics-research_agilusdiagnostics-deciphergenomics-yourgenehealth-activity-7405127837353009152-aeV0

This marks the third product launch of 2025 for Novacyt Group, with Primerdesign’s Exsig® Mag RapidBead Pro released on 19 November following two earlier launches from Yourgene Health. It will be important to see what and where the revenue is coming from across these products, as each targets a different market segment and revenue model.

13 Feb 2025 – IONA® Care+ (Yourgene Health): a prenatal blood test that checks for genetic conditions in babies before birth.

15 Jul 2025 – LightBench® Discover (Yourgene Health): a lab instrument that measures, sorts, and checks DNA quality for genomic research.

19 Nov 2025 – Exsig® Mag RapidBead Pro (Primerdesign): a next‑generation kit that speeds up DNA/RNA extraction from samples using magnetic beads.

Yourgene Health’s senior director Dr. Michael Richardson joined international experts to spotlight cutting-edge advances like Non-Invasive Prenatal Testing (NIPT). Their involvement underscored the importance of global industry leaders in bringing high-accuracy genetic screening to India, helping bridge awareness gaps and expand access to early detection of chromosomal disorders.

"India is now ranked just behind the US and China in terms of publications and start-ups in genomics." -

https://www.telegraphindia.com/west-bengal/kolkata/experts-push-for-genetic-test-before-childbirth-prnt/cid/2129275

I understand your point, and you're right — the lack of revenue growth since the Mpox outbreak is disappointing. That said, having the capability to assist and maintaining a presence in the market still counts. It means the infrastructure is in place, the expertise is available, and if the need arises, we're positioned to contribute meaningfully. It's not about hoping for a crisis — it's about being prepared to help if one unfolds.

With the WHO announcing the outbreak of Rift Valley fever in Mauritania and Senegal this week, again, the company is in a position to assist if needed. - https://www.primerdesign.co.uk/products/qpcr/rift-valley-fever-virus-rvfv/

The UK Health Security Agency (UKHSA) reported on November 7, 2025, that the risk of the more severe Clade Ib mpox strain entering the UK has increased from medium to high. This follows confirmed community transmission of Clade Ib in Europe and the US. Clade Ib has a higher fatality rate than the Clade IIb strain previously seen, and the UKHSA is urging eligible individuals to complete their vaccinations. More information is available on the UK Health Security Agency website.

https://www.gov.uk/government/publications/monkeypox-outbreak-epidemiological-overview/mpox-outbreak-epidemiological-overview-7-november-2025

Novacyt, through its Primerdesign brand, offers ready-to-use genesig kits to assist health authorities with rapid, accurate testing and differentiation of all major mpox clades. - https://www.primerdesign.co.uk/products/qpcr/genesigplex-kit-for-mpox-differentiation-of-clades-ia-ib-and-ii/

Space might have to wait — for now, Yourgene Health is steadily expanding its presence on the international scene. Compared to last year’s lineup, this winter period brings a more refined and purposeful schedule, with new additions like Assises de Génétique in Cannes and ASCO GI in San Francisco. It’s a measured step forward that reflects growing engagement in oncology, rare disease diagnostics, and NHS genomics.

Yourgene Health – Conference Attendance (Nov 2025 to Jan 2026)

ESPT 2025 – 5–7 Nov, Rotterdam 🇳🇱 | Stand 4 | Pharmacogenomics, DPYD testing

ASCO GI 2026 – 8–9 Jan, San Francisco 🇺🇸 | Table #51 | Oncology, DPYD genotyping

PAG 33 – 9–14 Jan, San Diego 🇺🇸 | Stand 425 | Genomics tools and solutions

Festival of Genomics London 2026 – Late Jan, London 🇬🇧 | Stand 177 | NHS genomics, clinical diagnostics

Assises de Génétique 2026 – 27–30 Jan, Cannes 🇫🇷 | Booth TBC | Human and medical genetics, rare diseases

Yourgene Health – Conference Attendance (Nov 2024 to Jan 2025)

ESPT 2024 – 6–8 Nov, Porto 🇵🇹 | Stand 3 | Pharmacogenomics, DPYD testing

PAG 32 – 13–18 Jan, San Diego 🇺🇸 | Stand 412 | Genomics tools, long-read sequencing

Festival of Genomics London 2025 – 24–25 Jan, London 🇬🇧 | Stand 165 | NHS genomics, clinical diagnostics

Https://bidstats.uk/tenders/2025/W43/857145875

The NHS is making a big move by handing out long-term deals to seven hospital trusts to handle all the genetic testing stuff. It's a huge commitment, with a budget of over £5 billion, showing they're serious about bringing this kind of high-tech medicine to more people.

Now, for Novacyt and their Yourgene products, this is a great thing. Instead of constantly chasing smaller contracts, they can focus on supplying these seven big regional centers. They've already done well with the NHS, like when they sold their DPYD kit to NHS Wales for chemo screening, their IONA® Nx prenatal testing workflow landed a deal with St George's NHS Trust and the June tender win with Cambridge University Hospitals NHS Trust. This puts them in a strong position to become a key long-term partner with these new hubs.

Topped up this morning for that reason

Would be nice to see Novacyt highlighting any collaboration work they do with the community - 3 separate sources have picked up on already. An RNS would not be nessasary but a linkedin post etc would be good to see.

https://standupforsouthport.com/biograd-donates-lab-equipment-worth-65000-with-free-training-for-teachers-to-boost-thousands-of-science-students-in-southport/

https://growthplatform.org/news/2025/04/biograd-partners-with-novacyt-to-donate-65000-in-industry-grade-laboratory-equipment-to-support-over-9500-local-students-in-science-education/

https://lbndaily.co.uk/liverpool-lab-firm-donates-equipment-to-schools/

A couple of days ago now but 0.90 by the end of the month

4:20 - 5:06 about EQTEC

https://www.share-talk.com/traders-cafe-with-zak-mir-bulletin-board-heroes-weekend-edition-sunday-13th-april-2025/